company background image
688266 logo

Suzhou Zelgen BiopharmaceuticalsLtd SHSE:688266 Stock Report

Last Price

CN¥69.57

Market Cap

CN¥18.4b

7D

8.6%

1Y

41.2%

Updated

29 Nov, 2024

Data

Company Financials +

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

SHSE:688266 Stock Report

Market Cap: CN¥18.4b

688266 Stock Overview

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. More details

688266 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Suzhou Zelgen BiopharmaceuticalsLtd
Historical stock prices
Current Share PriceCN¥69.57
52 Week HighCN¥79.99
52 Week LowCN¥33.20
Beta0.64
11 Month Change11.19%
3 Month Change25.87%
1 Year Change41.17%
33 Year Change10.43%
5 Year Changen/a
Change since IPO-6.73%

Recent News & Updates

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors

Nov 27
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors

Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 11
Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates

Recent updates

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors

Nov 27
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors

Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 11
Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates

What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates

May 08
What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up

Mar 06
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up

Shareholder Returns

688266CN BiotechsCN Market
7D8.6%3.1%2.3%
1Y41.2%-19.3%5.6%

Return vs Industry: 688266 exceeded the CN Biotechs industry which returned -20% over the past year.

Return vs Market: 688266 exceeded the CN Market which returned 4.2% over the past year.

Price Volatility

Is 688266's price volatile compared to industry and market?
688266 volatility
688266 Average Weekly Movement8.3%
Biotechs Industry Average Movement8.9%
Market Average Movement8.4%
10% most volatile stocks in CN Market12.7%
10% least volatile stocks in CN Market5.6%

Stable Share Price: 688266 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688266's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009858Zelin Shengwww.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Fundamentals Summary

How do Suzhou Zelgen BiopharmaceuticalsLtd's earnings and revenue compare to its market cap?
688266 fundamental statistics
Market capCN¥18.42b
Earnings (TTM)-CN¥174.40m
Revenue (TTM)CN¥488.45m

37.7x

P/S Ratio

-105.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688266 income statement (TTM)
RevenueCN¥488.45m
Cost of RevenueCN¥37.00m
Gross ProfitCN¥451.45m
Other ExpensesCN¥625.85m
Earnings-CN¥174.40m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Dec 03, 2024

Earnings per share (EPS)-0.66
Gross Margin92.43%
Net Profit Margin-35.70%
Debt/Equity Ratio68.6%

How did 688266 perform over the long term?

See historical performance and comparison